Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02160626 · ClinicalTrials.gov registry record · Phase 2
Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis
A Phase 2 study, sponsored by Aclaris Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 172
- Enrollment target
NCT02160626 is a Phase 2 study that has completed, run by Aclaris Therapeutics. The registered enrollment target is 172 participants.
The verdict
NCT02160626, a Phase 2 study, has completed, sponsored by Aclaris Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 172 participants
- Enrollment target
Study Summary
The main objective of this study is to evaluate the dose-response relationship of two concentrations of A-101 solution when applied to individual seborrheic keratosis (SK) lesions (target lesions) compared with a matching A-101 Solution Vehicle.
Interventions
- DRUG A-101 Vehicle
- DRUG A-101 (40) Topical Solution
- DRUG A-101 (32.5) Topical Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2014-06 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02160626
The ClinicalTrials.gov registry entry for NCT02160626 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 172 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aclaris Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which A-101 Vehicle is the first listed.
NCT02160626 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02160626 about?
NCT02160626 is a clinical study titled "Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis". The main objective of this study is to evaluate the dose-response relationship of two concentrations of A-101 solution when applied to individual seborrheic keratosis (SK) lesions (target lesions) compared with a matching A-101 Solution Vehicle.
What is the current status of trial NCT02160626?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 172 participants. The study started on 2014-06. Estimated completion is 2014-12.
What interventions are being tested in trial NCT02160626?
The interventions under investigation include: A-101 Vehicle (DRUG), A-101 (40) Topical Solution (DRUG), A-101 (32.5) Topical Solution (DRUG).
Who is sponsoring clinical trial NCT02160626?
This trial is sponsored by Aclaris Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.